Why Cagrilintide Costs So Much (and 5 Ways to Pay Less)

Cagrilintide at a glance:

• Drug class: Long-acting amylin analog
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection
• Typical frequency: once weekly
• Half-life: approximately 7 days
• Receptor target: amylin receptors (calcitonin receptor + RAMP)

Let's get specific about Cagrilintide pricing in 2026. Cash pricing depends on source and varies widely. What you actually pay depends on insurance status, manufacturer programs, and whether you use a discount card.

Cagrilintide Cash Price

Cagrilintide is not consistently available through licensed US pharmacies, so a "list price" is hard to pin down. Compounded or grey-market pricing varies dramatically.

That number is the starting point — what you actually pay depends on:

• Insurance status (commercial, Medicare, Medicaid, uninsured)
• Manufacturer savings programs (where applicable)
• Discount cards (GoodRx, Cost Plus Drug, manufacturer cards)
• Telehealth bundling (some platforms include the drug in a flat monthly fee)
• Pharmacy choice (chain vs independent vs mail-order)

Insurance Coverage

Coverage for Cagrilintide depends on the specific plan and the indication being treated. For FDA-approved indications, prior authorization is the most common gate. For off-label use, coverage is generally not available.

The pattern across the GLP-1 / metabolic medication space is: coverage for diabetes is widespread, coverage for weight loss is improving but still inconsistent, and coverage for any off-label use is rare.

Manufacturer Programs

Novo Nordisk runs savings programs for eligible patients. Eligibility usually requires commercial insurance and an active prescription. Patients on Medicare or Medicaid generally aren't eligible.

Cash-Pay and Direct-from-Manufacturer Options

Several manufacturers have introduced direct-to-consumer cash channels for their GLP-1 products in response to coverage gaps. These can lower the cash price meaningfully — see our guide to getting GLP-1 medications for current options.

Total Cost Over a Year

A monthly price of $1,000-$1,500 translates to roughly $10,800-$18,000 per year out of pocket without insurance. That's a real number to plan around — many programs that look attractive at $200/month for the first three months reset to full price after the introductory window.

For weight management, the relevant question is whether to plan around long-term use; for GLP-1 medications, weight regain after stopping is well-documented.

Comparing to Alternatives

The closest approved comparator is pramlintide (immediate-release amylin analog used with insulin). Some of those alternatives may be cheaper, covered when Cagrilintide isn't, or just better-suited for a particular case. See our cost comparison pages: linked above.

Bottom Line

Don't take the first quoted price as final. Pharmacy choice, savings programs, and direct-pay channels can move the number significantly.

Frequently Asked Questions

Related Reading

• The Honest Guide to Cagrilintide: What Patients and Doctors Actually Say
• Cagrilintide Side Effects: 7 Things to Watch For (and How to Manage Them)
• Cagrilintide Results: Realistic Expectations vs. Trial Headlines
• Cagrilintide and Weight Loss: What Trials Show vs. Real Life
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.

Pricing changes frequently. The numbers on this page reflect publicly available information as of 2026-04-29 and should be verified at the point of purchase.